BioSpace News Archive

Cocrystal Pharma, Inc. reports financial results for the three and six months ended June 30, 2021, and provides updates on its antiviral pipeline, milestones and business activities.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to announce the completion of its acquisition of EasyDNA (‘the acquisition’) for US$4 million in cash and stock on August 13, 2021.

Gracell Biotechnologies Inc. today announced an exclusive license agreement with FutureGen Biopharm (“FutureGen”), an innovative biopharmaceutical company, to develop engineered immune cell therapies targeting Claudin 18.2 (“CLDN18.2") in solid tumors.

Viracta Therapeutics, Inc. today announced the appointments of Flavia Borellini , Ph.D., and Jane F. Barlow , M.D., MPH, MBA, as independent members to Viracta’s Board of Directors.

Fresenius Medical Care North America and Cigna announce an expansion of their national effort to improve health outcomes and lower the cost of care for people living with kidney failure, or end stage renal disease.

Virtual Incision Corporation, a medical device company pioneering first-of-its-kind miniaturized robots for laparoscopic surgery, announced that the world’s first surgery using the MIRA™ Surgical Platform has been successfully performed by Michael A. Jobst, M.D., at Bryan Medical Center in Lincoln, Neb.

Avinger, Inc. today announced presentations featuring the Company’s Lumivascular, OCT-guided, technologies at the annual AMP (Amputation Prevention Symposium) conference occurring last week.

9 Meters Biopharma, Inc., a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced a collaboration with the European Biomedical Research Institute of Salerno, Italy to study larazotide for the treatment of multisystem inflammatory syndrome in children.

Avidity Biosciences, Inc. today announced its collaboration with the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (FSHD CTRN) to support a natural history study for people living with FSHD called the Motor Outcomes to Validate Evaluations Plus (MOVE+) Study.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, and Nasir Egal, Ph.D. as Senior Vice President, Quality Assurance.